2025
SJR Q1
JCR Q1 · 4,8
OA
9 matched articles
SCIE
Journal detail
International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
1461145714695111
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,651
- Quartile Q1
- H-Index 135
- Cites/doc 4,67
- Docs (3y) 236
- Cites (3y) 1.198
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 4,8
- 5Y JIF 5,3
- JCI 1,07
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Pharmacology Q1
- Pharmacology (medical) Q1
- Psychiatry and Mental Health Q1
Areas
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Clinical Neurology | Neurosciences | Pharmacology & Pharmacy | Psychiatry
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,651 | 4,8 | 5,3 | 1,07 | Q1 | 135 |
| 2024 | Q1 | Q1 | 1,585 | 3,7 | 4,8 | 1,16 | Q1 | 130 |
| 2023 | Q1 | Q1 | 1,525 | 4,5 | 4,7 | 1,15 | Q1 | 130 |
| 2022 | Q1 | Q1 | 1,406 | 4,8 | 5,1 | 1,22 | Q1 | 130 |
| 2021 | Q1 | Q1 | 1,417 | 5,7 | 6 | 1,21 | Q1 | 130 |
| 2020 | Q1 | Q1 | 1,897 | 5,2 | 5,2 | 1,32 | Q1 | 130 |
| 2019 | Q1 | Q1 | 1,695 | 4,3 | 4,4 | 1,28 | Q1 | 130 |
| 2018 | — | Q1 | — | 4,2 | 4,4 | 1,23 | Q1 | — |
| 2017 | Q1 | Q1 | 1,808 | 4 | 4,4 | 1,31 | Q1 | 130 |
| 2016 | Q1 | Q1 | 1,997 | 4,7 | 4,4 | — | — | 130 |
| 2015 | Q1 | Q1 | 1,764 | 4,3 | 4,5 | — | — | 130 |
| 2014 | Q1 | Q1 | 1,924 | 4 | 4,5 | — | — | 130 |
| 2013 | Q1 | Q1 | 2,121 | 5,3 | 5,1 | — | — | 130 |
| 2012 | Q1 | Q1 | 2,131 | 5,6 | 5,1 | — | — | 130 |
| 2011 | Q1 | Q1 | 1,998 | 4,6 | 4,7 | — | — | 130 |
| 2010 | Q1 | Q1 | 1,892 | 4,7 | 4,7 | — | — | 130 |
| 2009 | — | Q1 | — | 4,9 | 4,6 | — | — | — |
| 2008 | — | Q1 | — | 4,4 | 4,6 | — | — | — |
| 2007 | — | Q1 | — | 4,9 | 4,8 | — | — | — |
| 2006 | — | Q1 | — | 5,2 | — | — | — | — |
| 2005 | — | Q1 | — | 4 | — | — | — | — |
| 2004 | — | Q1 | — | 4,1 | — | — | — | — |
| 2003 | — | Q1 | — | 4 | — | — | — | — |
| 2002 | — | Q1 | — | 3,3 | — | — | — | — |
| 2001 | — | Q1 | — | 2,8 | — | — | — | — |
| 2000 | — | Q2 | — | 1,3 | — | — | — | — |
| 1999 | — | Q2 | — | 1,8 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 42/296 |
| 2025 | NEUROSCIENCES | SCIE | Q1 | Q1 | 73/330 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 77/356 |
| 2025 | PSYCHIATRY | SCIE | Q1 | Q1 | 47/293 |
| 2024 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 66/286 |
| 2024 | NEUROSCIENCES | SCIE | Q2 | Q1 | 100/314 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 99/352 |
| 2024 | PSYCHIATRY | SCIE | Q1 | Q1 | 63/288 |
| 2023 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 42/280 |
| 2023 | NEUROSCIENCES | SCIE | Q1 | Q1 | 70/310 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 60/354 |
| 2023 | PSYCHIATRY | SCIE | Q1 | Q1 | 45/279 |
| 2022 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 49/212 |
| 2022 | NEUROSCIENCES | SCIE | Q2 | Q1 | 80/272 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 65/278 |
| 2022 | PSYCHIATRY | SCIE | Q2 | Q1 | 50/155 |
| 2021 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 42/212 |
| 2021 | NEUROSCIENCES | SCIE | Q2 | Q1 | 70/275 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 58/279 |
| 2021 | PSYCHIATRY | SCIE | Q2 | Q1 | 45/155 |
| 2020 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 45/208 |
| 2020 | NEUROSCIENCES | SCIE | Q2 | Q1 | 77/273 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 58/276 |
| 2020 | PSYCHIATRY | SCIE | Q1 | Q1 | 34/156 |
| 2019 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 42/204 |
| 2019 | NEUROSCIENCES | SCIE | Q2 | Q1 | 76/272 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 47/271 |
| 2019 | PSYCHIATRY | SCIE | Q1 | Q1 | 33/155 |
| 2018 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 40/199 |
| 2018 | NEUROSCIENCES | SCIE | Q2 | Q1 | 73/267 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 45/267 |
| 2018 | PSYCHIATRY | SCIE | Q1 | Q1 | 30/146 |
| 2017 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 42/197 |
| 2017 | NEUROSCIENCES | SCIE | Q2 | Q1 | 71/261 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 42/261 |
| 2017 | PSYCHIATRY | SCIE | Q1 | Q1 | 32/142 |
| 2016 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 28/194 |
| 2016 | NEUROSCIENCES | SCIE | Q1 | — | 51/259 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 29/257 |
| 2016 | PSYCHIATRY | SCIE | Q1 | — | 23/142 |
| 2015 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 35/193 |
| 2015 | NEUROSCIENCES | SCIE | Q1 | — | 62/256 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 40/255 |
| 2015 | PSYCHIATRY | SCIE | Q1 | — | 28/142 |
| 2014 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 30/192 |
| 2014 | NEUROSCIENCES | SCIE | Q2 | — | 65/252 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 40/255 |
| 2014 | PSYCHIATRY | SCIE | Q1 | — | 27/140 |
| 2013 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 19/194 |
| 2013 | NEUROSCIENCES | SCIE | Q1 | — | 42/252 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 20/256 |
| 2013 | PSYCHIATRY | SCIE | Q1 | — | 18/136 |
| 2012 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 14/193 |
| 2012 | NEUROSCIENCES | SCIE | Q1 | — | 32/252 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 15/261 |
| 2012 | PSYCHIATRY | SCIE | Q1 | — | 13/135 |
| 2011 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 22/192 |
| 2011 | NEUROSCIENCES | SCIE | Q1 | — | 50/244 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 29/261 |
| 2011 | PSYCHIATRY | SCIE | Q1 | — | 20/130 |
| 2010 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 24/185 |
| 2010 | NEUROSCIENCES | SCIE | Q1 | — | 46/239 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 24/252 |
| 2010 | PSYCHIATRY | SCIE | Q1 | — | 18/128 |
| 2009 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 18/167 |
| 2009 | NEUROSCIENCES | SCIE | Q1 | — | 42/231 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 23/237 |
| 2009 | PSYCHIATRY | SCIE | Q1 | — | 16/117 |
| 2008 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 18/156 |
| 2008 | NEUROSCIENCES | SCIE | Q1 | — | 43/221 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 28/219 |
| 2008 | PSYCHIATRY | SCIE | Q1 | — | 14/101 |
| 2007 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 12/146 |
| 2007 | NEUROSCIENCES | SCIE | Q1 | — | 32/211 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 17/205 |
| 2007 | PSYCHIATRY | SCIE | Q1 | — | 10/94 |
| 2006 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 11/147 |
| 2006 | NEUROSCIENCES | SCIE | Q1 | — | 27/200 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 20/199 |
| 2006 | PSYCHIATRY | SCIE | Q1 | — | 8/94 |
| 2005 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 17/148 |
| 2005 | NEUROSCIENCES | SCIE | Q1 | — | 46/200 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 30/193 |
| 2005 | PSYCHIATRY | SCIE | Q1 | — | 15/94 |
| 2004 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 10/140 |
| 2004 | NEUROSCIENCES | SCIE | Q1 | — | 35/198 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 27/187 |
| 2004 | PSYCHIATRY | SCIE | Q1 | — | 10/90 |
| 2003 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 9/135 |
| 2003 | NEUROSCIENCES | SCIE | Q1 | — | 33/198 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 24/185 |
| 2003 | PSYCHIATRY | SCIE | Q1 | — | 10/87 |
| 2002 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 17/138 |
| 2002 | NEUROSCIENCES | SCIE | Q1 | — | 46/197 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 28/188 |
| 2002 | PSYCHIATRY | SCIE | Q1 | — | 11/88 |
| 2001 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 21/136 |
| 2001 | NEUROSCIENCES | SCIE | Q2 | — | 57/198 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 34/186 |
| 2001 | PSYCHIATRY | SCIE | Q1 | — | 18/81 |
| 2000 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 61/137 |
| 2000 | NEUROSCIENCES | SCIE | Q3 | — | 124/203 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 87/181 |
| 2000 | PSYCHIATRY | SCIE | Q3 | — | 49/82 |
| 1999 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 46/132 |
| 1999 | NEUROSCIENCES | SCIE | Q2 | — | 94/201 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 54/175 |